Bevacizumab (Avastin), which inhibits vascular endothelial growth factor (VEGF) from binding to its receptors, is an anti-cancer drug considered for treating glioblastoma (high-grade glioma) [123] and ovarian cancer [124]. The gene discussed is VEGFA; the disease is cancer.